

Fotios Loupakis

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2227424/fotios-loupakis-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| | | | |
|--------------------|--------------------------|----------------|-----------------|
| 329 papers | 12,169 citations | 54 h-index | 105 g-index |
| 361 ext. papers | 14,713 ext. citations | 5.7 avg, IF | 5.93 L-index |

| # | Paper | IF | Citations |
|-----|--|------|-----------|
| 329 | Complete pathological response of colorectal peritoneal metastases in Lynch syndrome after immunotherapy case report: is a paradigm shift in cytoreductive surgery needed?. <i>BMC Gastroenterology</i> , 2022 , 22, 17 | 3 | 0 |
| 328 | Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF-mutant metastatic and/or unresectable colorectal cancer.. <i>Critical Reviews in Oncology/Hematology</i> , 2022 , 173, 103646 | 7 | 0 |
| 327 | Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN study.. <i>European Journal of Cancer</i> , 2022 , 166, 165-175 | 7.5 | 1 |
| 326 | Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas. <i>Journal of Personalized Medicine</i> , 2021 , 11, | 3.6 | 4 |
| 325 | RNA-Binding Protein Polymorphisms as Novel Biomarkers to Predict Outcomes of Metastatic Colorectal Cancer: A Meta-analysis from TRIBE, FIRE-3, and MAVERICC. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1153-1160 | 6.1 | 0 |
| 324 | NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. <i>Modern Pathology</i> , 2021 , 34, 1547-1557 | 9.8 | 5 |
| 323 | RAS as a positive predictive biomarker: focus on lung and colorectal cancer patients. <i>European Journal of Cancer</i> , 2021 , 146, 74-83 | 7.5 | 8 |
| 322 | MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. <i>Biomedicines</i> , 2021 , 9, | 4.8 | 2 |
| 321 | Molecular profiling of appendiceal serrated lesions, polyps and mucinous neoplasms: a single-centre experience. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 1897-1904 | 4.9 | 1 |
| 320 | The Role of p53 Expression in Patients with RAS/BRAF Wild-Type Metastatic Colorectal Cancer Receiving Irinotecan and Cetuximab as Later Line Treatment. <i>Targeted Oncology</i> , 2021 , 16, 517-527 | 5 | 1 |
| 319 | Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , 2021 , 22, 779-789 | 21.7 | 53 |
| 318 | Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2021 , 11, 12191 | 4.9 | 0 |
| 317 | Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021 , 150, 133-142 | 7.5 | 1 |
| 316 | Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases. <i>JCO Precision Oncology</i> , 2021 , 5, | 3.6 | 9 |
| 315 | Outcome of patients with colorectal cancer undergoing lung metastases resection: a single-institution retrospective analysis. <i>Tumori</i> , 2021 , 107, 46-54 | 1.7 | 2 |
| 314 | Hurrying up but not rushing, acting and not reacting, good sense and not common sense: Open thoughts and reasonable doubts on COVID-19 vaccination strategies in cancer patients. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 167, 103271 | 7 | 1 |
| 313 | Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 273-284 | 2.2 | 60 |

| | | | |
|-----|---|------|----|
| 312 | Clinical significance of enterocyte-specific gene polymorphisms as candidate markers of oxaliplatin-based treatment for metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2021 , 21, 285-295 | 3.5 | 0 |
| 311 | Synaptophysin expression in mutated advanced colorectal cancers identifies a new subgroup of tumours with worse prognosis. <i>European Journal of Cancer</i> , 2021 , 146, 145-154 | 7.5 | 6 |
| 310 | Epstein-Barr virus associated gastric dysplasia: a new rare entity?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1 | 5.1 | 0 |
| 309 | Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020 , 25, 803-809 | 5.7 | 17 |
| 308 | The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials. <i>British Journal of Cancer</i> , 2020 , 123, 403-409 | 8.7 | 22 |
| 307 | Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. <i>Gastric Cancer</i> , 2020 , 23, 1064-1074 | 7.6 | 4 |
| 306 | Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020 , 135, 78-88 | 7.5 | 5 |
| 305 | Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer. <i>Scientific Reports</i> , 2020 , 10, 9778 | 4.9 | 1 |
| 304 | KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 219-225 | 3.8 | 16 |
| 303 | Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2020 , 21, 107-117 | 21.7 | 98 |
| 302 | Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. <i>Cancers</i> , 2020 , 12, | 6.6 | 2 |
| 301 | Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes. <i>Oncologist</i> , 2020 , 25, 481-487 | 5.7 | 43 |
| 300 | The heterogeneous clinical and pathological landscapes of metastatic -mutated colorectal cancer. <i>Cancer Cell International</i> , 2020 , 20, 30 | 6.4 | 22 |
| 299 | A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials. <i>European Journal of Cancer</i> , 2020 , 131, 89-97 | 7.5 | 3 |
| 298 | Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4001-4001 | 2.2 | 22 |
| 297 | Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial. <i>European Journal of Cancer</i> , 2020 , 133, 66-73 | 7.5 | 4 |
| 296 | PD-L1 expression in gastroesophageal dysplastic lesions. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020 , 477, 151-156 | 5.1 | 10 |
| 295 | A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. <i>PLoS ONE</i> , 2020 , 15, e0239439 | 3.7 | 3 |

| | | | |
|-----|--|------|-----|
| 294 | Practical considerations in the use of regorafenib in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020 , 12, 1758835920956862 | 5.4 | 6 |
| 293 | Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer 2020 , 8, | | 4 |
| 292 | Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. <i>Cancers</i> , 2020 , 12, | 6.6 | 3 |
| 291 | Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study. <i>Cells</i> , 2020 , 9, | 7.9 | 7 |
| 290 | Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020 , 147, 2303-2315 | 7.5 | 7 |
| 289 | Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 191-199.e6 | 3.8 | 10 |
| 288 | CK7 and consensus molecular subtypes as major prognosticators in BRAF mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2019 , 121, 593-599 | 8.7 | 14 |
| 287 | Negative Hyperselection of Patients With and Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3099-3110 | 2.2 | 35 |
| 286 | Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 245-256.e5 | 3.8 | 0 |
| 285 | Encorafenib, Binimetinib, and Cetuximab in V600E-Mutated Colorectal Cancer. <i>New England Journal of Medicine</i> , 2019 , 381, 1632-1643 | 59.2 | 481 |
| 284 | Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenib. <i>Pharmacogenomics Journal</i> , 2019 , 19, 455-464 | 3.5 | 3 |
| 283 | Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431 | 17.4 | 45 |
| 282 | An overview on clinical, pathological and molecular features of lung metastases from colorectal cancer. <i>Expert Review of Respiratory Medicine</i> , 2019 , 13, 635-644 | 3.8 | 2 |
| 281 | Quantitative evidence for early metastatic seeding in colorectal cancer. <i>Nature Genetics</i> , 2019 , 51, 1113-1122 | 36.2 | 164 |
| 280 | Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases. <i>British Journal of Cancer</i> , 2019 , 121, 257-263 | 8.7 | 20 |
| 279 | Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3. <i>European Journal of Cancer</i> , 2019 , 111, 138-147 | 7.5 | 3 |
| 278 | AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3. <i>International Journal of Cancer</i> , 2019 , 145, 2082-2090 | 7.5 | 0 |
| 277 | Class 1, 2, and 3 -Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization. <i>Clinical Cancer Research</i> , 2019 , 25, 3954-3961 | 12.9 | 36 |

| | | | |
|-----|--|-----|----|
| 276 | Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. <i>ESMO Open</i> , 2019 , 4, e000489 | 6 | 8 |
| 275 | Ramucirumab: the long and winding road toward being an option for mCRC treatment. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 399-409 | 5.4 | 3 |
| 274 | Chemotherapeutic and antiangiogenic drugs beyond tumor progression in colon cancer: Evaluation of the effects of switched schedules and related pharmacodynamics. <i>Biochemical Pharmacology</i> , 2019 , 164, 94-105 | 6 | 9 |
| 273 | DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. <i>Pharmacogenomics Journal</i> , 2019 , 19, 556-563 | 3.5 | 20 |
| 272 | Novel Common Genetic Susceptibility Loci for Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 146-157 | 9.7 | 67 |
| 271 | Tumor mutation burden: from comprehensive mutational screening to the clinic. <i>Cancer Cell International</i> , 2019 , 19, 209 | 6.4 | 74 |
| 270 | Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients' Prognosis. <i>International Journal of Surgical Pathology</i> , 2019 , 27, 816-835 | 1.2 | 4 |
| 269 | A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study. <i>European Journal of Cancer</i> , 2019 , 118, 121-130 | 7.5 | 29 |
| 268 | Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A. <i>EBioMedicine</i> , 2019 , 45, 139-154 | 8.8 | 19 |
| 267 | High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Frontiers in Oncology</i> , 2019 , 9, 622 | 5.3 | 17 |
| 266 | Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR status 2019 , 7, 297 | | 10 |
| 265 | PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target. <i>Cancers</i> , 2019 , 11, | 6.6 | 30 |
| 264 | BRCA1 genetic variant to predict survival in metastatic colorectal cancer (mCRC) patients (pts) treated with FOLFIRI/bevacizumab (bev): Results from phase III TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3145-3145 | 2.2 | 2 |
| 263 | Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives. <i>World Journal of Gastroenterology</i> , 2019 , 25, 5773-5788 | 5.6 | 45 |
| 262 | Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 594-594 | 2.2 | |
| 261 | Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 566-566 | 2.2 | |
| 260 | Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 558-558 | 2.2 | |
| 259 | Genetic variants in RNA binding protein (RBP) to predict outcome in metastatic colorectal cancer (mCRC): Data from FIRE-3, TRIBE, and MAVERICC trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3545-3545 ^{2.2} | | |

| | | | |
|-----|---|------|----|
| 258 | Polymorphisms in the dopamine (DA) signaling to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE, MAVERICC, and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3048-3048 | 2.2 | 0 |
| 257 | Another Chapter of the : Is Primary Tumor Location a Prognostic Feature in Mutant Metastatic Colorectal Cancer?. <i>Oncologist</i> , 2019 , 24, e77-e79 | 5.7 | 3 |
| 256 | Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy. <i>Clinical Colorectal Cancer</i> , 2019 , 18, e8-e19 | 3.8 | 9 |
| 255 | miR-224 Is Significantly Upregulated and Targets Caspase-3 and Caspase-7 During Colorectal Carcinogenesis. <i>Translational Oncology</i> , 2019 , 12, 282-291 | 4.9 | 10 |
| 254 | Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies. <i>Drug Safety</i> , 2019 , 42, 159-179 | 5.1 | 13 |
| 253 | Safety and Tolerability of c-MET Inhibitors in Cancer. <i>Drug Safety</i> , 2019 , 42, 211-233 | 5.1 | 40 |
| 252 | Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients. <i>Investigational New Drugs</i> , 2018 , 36, 709-714 | 4.3 | 5 |
| 251 | Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO. <i>Annals of Oncology</i> , 2018 , 29, 1528-1534 | 10.3 | 58 |
| 250 | Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e471-e488 | 3.8 | 4 |
| 249 | The role of tumor angiogenesis as a therapeutic target in colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 251-266 | 3.5 | 29 |
| 248 | Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e395-e414 | 3.8 | 16 |
| 247 | Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2018 , 18, 623-632 | 3.5 | 4 |
| 246 | The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients. <i>BMC Cancer</i> , 2018 , 18, 98 | 4.8 | 6 |
| 245 | Noninferiority of three months versus six months of oxaliplatin-based adjuvant chemotherapy for resected colon cancer. How should IDEA findings affect clinical practice?. <i>International Journal of Cancer</i> , 2018 , 143, 2342-2350 | 7.5 | 5 |
| 244 | Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TROREADOR Study. <i>Clinical Colorectal Cancer</i> , 2018 , 17, e601-e615 | 3.8 | 8 |
| 243 | NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients. <i>PLoS ONE</i> , 2018 , 13, e0193640 | 3.7 | 3 |
| 242 | Polymorphism in the circadian clock pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3576-3576 | 2.2 | 1 |
| 241 | Clinico-pathological and molecular characterisation of BRAF mutant metastatic colorectal cancer (mCRC): Are all mutations created equal?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3590-3590 | 2.2 | 4 |

| | | | |
|-----|---|------|----|
| 240 | Clinical prognostic score of BRAF V600E mutated (BM) metastatic colorectal cancer (mCRC): Results from the BRAF, BeCool platform.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 639-639 | 2.2 | 2 |
| 239 | Polymorphism in cancer-associated fibroblasts (CAFs) related genes and clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) enrolled in two independent randomized phase III trials: TRIBE and FIRE-3.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 645-645 | 2.2 | 1 |
| 238 | Matrix metalloproteinase-related gene polymorphisms to predict efficacy of regorafenib in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 692-692 | 2.2 | 1 |
| 237 | Efficacy outcomes with bevacizumab added to chemotherapy (bev+CT) compared with chemotherapy alone (CT) in left- and right-sided tumors in metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 726-726 | 2.2 | 3 |
| 236 | and genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. <i>Oncotarget</i> , 2018 , 9, 7859-7866 | 3.3 | 18 |
| 235 | The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 651-651 | 2.2 | |
| 234 | Single nucleotide polymorphisms in miRNA binding sites of nucleotide excision repair-related genes to predict clinical benefit of oxaliplatin in FOLFOXIRI plus bevacizumab in TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 663-663 | 2.2 | |
| 233 | Polymorphisms in beta-defensin pathways and clinical outcomes in metastatic colorectal cancer patients treated with FOLFIRI-bevacizumab in two randomized phase III trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 662-662 | 2.2 | |
| 232 | Genetic variants in methylation and demethylation pathways to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/Bev: Data from TRIBE and FIRE-3 trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 646-646 | 2.2 | |
| 231 | Histopathologic response and growth patterns of colorectal cancer liver metastases (CRCLM) in patients treated with triplets plus bevacizumab (bev) or anti-EGFRs.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 636-636 | 2.2 | |
| 230 | Clinical significance of enterocyte-specific gene polymorphisms as candidate marker of oxaliplatin-based treatment for metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12066-12066 | 2.2 | |
| 229 | Genetic variants within the glucocorticoids related genes to predict outcome in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12098-12098 | 2.2 | |
| 228 | The impact of Th17 cell pathway-related genetic variants in metastatic colorectal cancer patients treated with bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15578-e15578 | 2.2 | |
| 227 | Genetic variation in TET3 and survival in metastatic colorectal cancer (mCRC) from FIRE-3, TRIBE, and MAVERICC clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3575-3575 | 2.2 | |
| 226 | A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab. <i>Clinical Cancer Research</i> , 2018 , 24, 784-793 | 12.9 | 14 |
| 225 | Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2052-2060 | 2.2 | 19 |
| 224 | The DISTINCTIVE study: A biologically enriched phase II study of second-line folfiri/aflibercept in prospectively stratified, anti-EGFR resistant, metastatic colorectal cancer patients with RAS Validated wild type status - Trial in progress. <i>Annals of Oncology</i> , 2018 , 29, v82 | 10.3 | 3 |
| 223 | Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2018 , 119, 1451-1455 | 8.7 | 14 |

| | | | |
|-----|--|------|----|
| 222 | Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy. <i>Nature Communications</i> , 2018 , 9, 4112 | 17.4 | 36 |
| 221 | LONG-NONCODING RNAs in gastroesophageal cancers. <i>Non-coding RNA Research</i> , 2018 , 3, 195-212 | 6 | 28 |
| 220 | Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases. <i>Cancer Cell International</i> , 2018 , 18, 131 | 6.4 | 6 |
| 219 | Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018 , 3, 40 | 5.2 | 39 |
| 218 | Glycolysis gene expression analysis and selective metabolic advantage in the clinical progression of colorectal cancer. <i>Pharmacogenomics Journal</i> , 2017 , 17, 258-264 | 3.5 | 55 |
| 217 | Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab. <i>Pharmacogenomics Journal</i> , 2017 , 17, 221-231 | 3.5 | 6 |
| 216 | Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2017 , 116, 318-323 | 8.7 | 20 |
| 215 | The role of pharmacogenetics in the new ESMO colorectal cancer guidelines. <i>Pharmacogenomics</i> , 2017 , 18, 197-200 | 2.6 | 7 |
| 214 | Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017 , 28, 1015-1022 | 10.3 | 20 |
| 213 | Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial. <i>International Journal of Cancer</i> , 2017 , 141, 383-392 | 7.5 | 5 |
| 212 | Immunotherapy for colorectal cancer: where are we heading?. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 709-721 | 5.4 | 71 |
| 211 | Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials. <i>European Journal of Cancer</i> , 2017 , 77, 13-20 | 7.5 | 15 |
| 210 | Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. <i>Clinical Cancer Research</i> , 2017 , 23, 4312-4322 | 12.9 | 27 |
| 209 | Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest. <i>European Journal of Cancer</i> , 2017 , 73, 74-84 | 7.5 | 32 |
| 208 | Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2017 , 86, 197-206 | 7.5 | 16 |
| 207 | QoL is a cool tool. <i>Annals of Oncology</i> , 2017 , 28, 2032-2033 | 10.3 | 2 |
| 206 | BRAF p.V600E-specific immunohistochemical assessment in colorectal cancer endoscopy biopsies is consistent with the mutational profiling. <i>Histopathology</i> , 2017 , 71, 1008-1011 | 7.3 | 8 |
| 205 | Tandem repeat variation near the HIC1 (hypermethylated in cancer 1) promoter predicts outcome of oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. <i>Cancer</i> , 2017 , 123, 4506-4514 | 6.4 | 14 |

| | | | |
|-----|---|------|----|
| 204 | Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. <i>Expert Opinion on Biological Therapy</i> , 2017 , 17, 1297-1308 | 5.4 | 17 |
| 203 | New perspectives for TAS-102: TASK successful?. <i>Lancet Oncology, The</i> , 2017 , 18, 1139-1141 | 21.7 | 1 |
| 202 | Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials. <i>Annals of Oncology</i> , 2017 , 28, 2780-2785 | 10.3 | 19 |
| 201 | Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017 , 2, e000241 | 6 | 6 |
| 200 | TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group. <i>BMC Cancer</i> , 2017 , 17, 408 | 4.8 | 20 |
| 199 | Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram. <i>Annals of Oncology</i> , 2017 , 28, 555-561 | 10.3 | 32 |
| 198 | CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy. <i>Pharmacogenomics Journal</i> , 2017 , 17, 543-550 | 3.5 | 9 |
| 197 | Genetic variants of genes in CCL5/CCR5 pathway to predict regorafenib-induced hand-foot skin reaction in patients with refractory metastatic colorectal cancer: A report of ethnic difference.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 615-615 | 2.2 | 1 |
| 196 | Stereotactic Body Radiotherapy in Patients with Lung Oligometastases from Colorectal Cancer. <i>Anticancer Research</i> , 2017 , 37, 315-319 | 2.3 | 16 |
| 195 | Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. <i>Cancer Research and Treatment</i> , 2017 , 49, 834-845 | 5.2 | 9 |
| 194 | Genetic variations in semaphorin/neuropilin signaling to predict clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving bevacizumab-based chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11608-11608 | 2.2 | |
| 193 | Partial splenic embolization in chemotherapy-induced thrombocytopenia: A retrospective analysis with long term follow-up.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21654-e21654 | 2.2 | |
| 192 | Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer. <i>Oncologist</i> , 2016 , 21, 988-94 | 5.7 | 72 |
| 191 | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients. <i>Scientific Reports</i> , 2016 , 6, 25195 | 4.9 | 19 |
| 190 | Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology. <i>Tumori</i> , 2016 , 102, 108-13 | 1.7 | 1 |
| 189 | Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): The phase II randomized MACBETH trial by GONO. <i>Annals of Oncology</i> , 2016 , 27, vi152 | 10.3 | 3 |
| 188 | Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1740-5 | 6.1 | 7 |
| 187 | CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 2184 | 59.2 | 12 |

| | | | |
|-----|--|------|----|
| 186 | FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials. <i>Annals of Oncology</i> , 2016 , 27, 843-9 | 10.3 | 36 |
| 185 | A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer. <i>Targeted Oncology</i> , 2016 , 11, 293-308 | 5 | 14 |
| 184 | Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2016 , 22, 3218-26 | 12.9 | 16 |
| 183 | Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2016 , 114, 30-6 | 8.7 | 39 |
| 182 | Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50 | 2.2 | 76 |
| 181 | Females versus males: Clinical features and outcome differences in large molecularly selected cohort of mCRC patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3540-3540 | 2.2 | 1 |
| 180 | Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): Results of the phase II randomized MACBETH trial by GONO.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3543-3543 | 2.2 | 9 |
| 179 | Genetic variants of ATM and XRCC3 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3579-3579 | 2.2 | 3 |
| 178 | Genetic variants of hENT-1 to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3580-3580 | 2.2 | 2 |
| 177 | Genetic variations associated with cancer cachexia pathways to predict survival in metastatic colorectal cancer (mCRC): Results from FIRE-3 and TRIBE.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3590-3590 | 2.2 | 1 |
| 176 | CDX2 as a Prognostic Biomarker in Colon Cancer. <i>New England Journal of Medicine</i> , 2016 , 374, 2183 | 59.2 | 5 |
| 175 | Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: A pooled analysis of GONO studies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15054-e15054 | 2.2 | |
| 174 | TRIBE-2 by GONO group: A phase III strategy study in the first- and second-line treatment of unresectable metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3629-TPS3629 | 2.2 | |
| 173 | Lactate dehydrogenase (LDH) levels to predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Subgroup analysis of the randomized BEBYP study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e15127-e15127 | 2.2 | |
| 172 | Randomized phase II study of first-line FOLFOX plus panitumumab (pan) versus 5FU plus pan in elderly RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts): The PANDA study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS3627-TPS3627 | 2.2 | |
| 171 | Genetic variants of Pin1 to predict benefit from irinotecan and oxaliplatin based treatment in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11589-11589 | 2.2 | |
| 170 | Identifying predictive SNPs in patients with metastatic colorectal cancer (mCRC) using Random Survival Forests.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3606-3606 | 2.2 | |
| 169 | NOS2 polymorphisms in the prediction of benefit from FOLFIRI plus bevacizumab in mCRC patients enrolled in TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11597-11597 | 2.2 | |

| | | | |
|-----|---|------|-----|
| 168 | Identifying SNPs associated with progression-free survival (PFS) and overall survival (OS) in patients with KRAS wildtype and mutant metastatic colorectal cancer (mCRC) using Random Survival Forests (RSF).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3604-3604 | 2.2 | |
| 167 | IRS1 and IRS2 polymorphisms and outcome in mCRC patients enrolled in the FIRE-3 trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11600-11600 | 2.2 | |
| 166 | Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients. <i>Oncology</i> , 2016 , 91, 283-288 | 3.6 | 1 |
| 165 | FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial. <i>Annals of Oncology</i> , 2016 , 27, vi560 | 10.3 | 4 |
| 164 | Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. <i>Annals of Oncology</i> , 2016 , 27, 1456-66 | 10.3 | 31 |
| 163 | Ramucirumab for the treatment of gastric cancers, colorectal adenocarcinomas, and other gastrointestinal malignancies. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 877-85 | 3.8 | 10 |
| 162 | Primary tumor location as a prognostic factor in metastatic colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 298 |
| 161 | First-line chemotherapy for mCRC: review and evidence-based algorithm. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 607-19 | 19.4 | 106 |
| 160 | BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. <i>Annals of Oncology</i> , 2015 , 26, 2092-7 | 10.3 | 110 |
| 159 | BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. <i>British Journal of Cancer</i> , 2015 , 112, 1921-8 | 8.7 | 111 |
| 158 | Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. <i>Annals of Oncology</i> , 2015 , 26, 1188-1194 | 10.3 | 112 |
| 157 | FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8 | 19.2 | 17 |
| 156 | Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials. <i>Annals of Oncology</i> , 2015 , 26, 2450-6 | 10.3 | 20 |
| 155 | Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2374-81 | 6.1 | 3 |
| 154 | BRAF-mutated metastatic colorectal cancer between past and future. <i>British Journal of Cancer</i> , 2015 , 113, 1634-5 | 8.7 | 10 |
| 153 | Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope. <i>Oncologist</i> , 2015 , 20, 1261-5 | 5.7 | 29 |
| 152 | TAS-102 for the treatment of metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1283-92 | 3.5 | 8 |
| 151 | Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. <i>Modern Pathology</i> , 2015 , 28, 1481-91 | 9.8 | 144 |

| | | | |
|-----|---|------|-----|
| 150 | Response. <i>Journal of the National Cancer Institute</i> , 2015 , 107, | 9.7 | 2 |
| 149 | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. <i>Lancet Oncology, The</i> , 2015 , 16, 1306-15 | 21.7 | 593 |
| 148 | Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer. <i>Annals of Oncology</i> , 2015 , 26, 2503 | 10.3 | 15 |
| 147 | Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ER-positive advanced breast cancer. <i>Pharmacogenomics Journal</i> , 2015 , 15, 235-40 | 3.5 | 1 |
| 146 | Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2015 , 136, 83-90 | 7.5 | 92 |
| 145 | Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. <i>Pharmacogenomics Journal</i> , 2015 , 15, 69-76 | 3.5 | 24 |
| 144 | TRIBE study: are all three cytotoxic drugs crucial? - Authors' reply. <i>Lancet Oncology, The</i> , 2015 , 16, e578-9 | 21.7 | |
| 143 | Molecular and pathological characterization of the EZH2 rs3757441 single nucleotide polymorphism in colorectal cancer. <i>BMC Cancer</i> , 2015 , 15, 874 | 4.8 | 8 |
| 142 | FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2015 , 372, 291-2 | 59.2 | 10 |
| 141 | Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. <i>Nature Medicine</i> , 2015 , 21, 795-801 | 50.5 | 557 |
| 140 | First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 96, 156-66 | 7 | 50 |
| 139 | TAS-102, a novel antitumor agent: a review of the mechanism of action. <i>Cancer Treatment Reviews</i> , 2015 , 41, 777-83 | 14.4 | 80 |
| 138 | Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 155-62 | 5.4 | 26 |
| 137 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. <i>Pharmacogenomics Journal</i> , 2015 , 15, 354-62 | 3.5 | 36 |
| 136 | Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. <i>Pharmacogenomics Journal</i> , 2015 , 15, 226-34 | 3.5 | 14 |
| 135 | Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. <i>Annals of Oncology</i> , 2015 , 26, 724-730 | 10.3 | 117 |
| 134 | FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as initial treatment for metastatic colorectal cancer (TRIBE study): Updated survival results and final molecular subgroups analyses.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3510-3510 | 2.2 | 6 |
| 133 | DPYD c.1905+1G>A and c.2846A>T and UGT1A1*28 allelic variants as predictors of toxicity: Pharmacogenetic translational analysis from the phase III TRIBE study in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3532-3532 | 2.2 | 2 |

| | | | |
|-----|--|------|-----|
| 132 | Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcome of bevacizumab (bev)-based treatment in patients with metastatic colorectal cancer (mCRC): Results from TRIBE and FIRE3 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3552-3552 | 2.2 | 1 |
| 131 | Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 595-595 | 2.2 | 1 |
| 130 | FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 657-657 | 2.2 | 5 |
| 129 | Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management. <i>Oncotarget</i> , 2015 , 6, 33982-92 | 3.3 | 39 |
| 128 | Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. <i>Oncotarget</i> , 2015 , 6, 31604-12 | 3.3 | 27 |
| 127 | Polymorphism of the chemokine CXCR4 to predict treatment benefit of first-line bevacizumab-based chemotherapy in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 635-635 | 2.2 | |
| 126 | Prognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: Implications for clinical management.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 591-591 | 2.2 | |
| 125 | Macrophage polarization related gene variants to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with bevacizumab (bev) in combination with FOLFIRI.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 621-621 | 2.2 | |
| 124 | Effect of genetic variation on overall survival in a clinical trial of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3562-3562 | 2.2 | |
| 123 | Genetic variant of TWEAK to predict clinical outcome in mCRC patients (pts) treated with first line FOLFIRI and Bevacizumab (FOLFIRI/BEV) in FIRE-3 and TRIBE cohorts.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3554-3554 | 2.2 | |
| 122 | Glucose metabolism enzymes gene expression analysis and selective metabolic advantage in the progression of colorectal cancer (CRC).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e14519-e14519 | 2.2 | |
| 121 | Prognostic significance of KRAS mutation rate in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e22075-e22075 | 2.2 | |
| 120 | Genetic variants of kinases suppressors of Ras (KSR) to predict tumor response to first-line cetuximab in patients with mCRC: Prospective analysis in the FIRE 3 trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3613-3613 | 2.2 | |
| 119 | Bevacizumab and first-line chemotherapy for older patients with advanced colorectal cancer: final results of a Community-based Observational Italian Study. <i>Anticancer Research</i> , 2015 , 35, 2391-9 | 2.3 | 1 |
| 118 | FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2014 , 50, 57-63 | 7.5 | 136 |
| 117 | Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1609-18 | 59.2 | 663 |
| 116 | Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. <i>Pharmacogenomics Journal</i> , 2014 , 14, 14-9 | 3.5 | 17 |
| 115 | Association of common gene variants in the WNT/βcatenin pathway with colon cancer recurrence. <i>Pharmacogenomics Journal</i> , 2014 , 14, 142-50 | 3.5 | 26 |

| | | | |
|-----|---|------|----|
| 114 | and genotyping of synchronous colorectal carcinomas. <i>Oncology Letters</i> , 2014 , 7, 1532-1536 | 2.6 | 5 |
| 113 | Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. <i>Pharmacogenomics Journal</i> , 2014 , 14, 135-41 | 3.5 | 10 |
| 112 | Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients. <i>Pharmacogenomics Journal</i> , 2014 , 14, 322-7 | 3.5 | 10 |
| 111 | Biomarkers and response to bevacizumab--letter. <i>Clinical Cancer Research</i> , 2014 , 20, 1056-7 | 12.9 | 8 |
| 110 | EGFR ligands as pharmacodynamic biomarkers in metastatic colorectal cancer patients treated with cetuximab and irinotecan. <i>Targeted Oncology</i> , 2014 , 9, 205-14 | 5 | 22 |
| 109 | Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3519-3529 | 3.2 | 7 |
| 108 | Phase II study of single-agent cetuximab in KRAS G13D mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3524-3524 | 2.2 | 5 |
| 107 | Modified FOLFOXIRI plus cetuximab (cet) as induction treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Preliminary results of the phase II randomized Macbeth trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3596-3596 | 2.2 | 4 |
| 106 | mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3640-3640 | 2.2 | 1 |
| 105 | Phase II randomized study of induction FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The MOMA trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS3664-TPS3664 | 2.2 | 1 |
| 104 | Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 521-521 | 2.2 | 2 |
| 103 | CCL2 polymorphism as a predictive marker for bevacizumab (Bev) in combination with FOLFIRI as first-line treatment in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14556-e14556 | 2.2 | 0 |
| 102 | Association of the prognostic role of CXCR4/CXCL12 polymorphism with treatment outcomes after bevacizumab-based chemotherapy in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22008-e22008 | 2.2 | |
| 101 | High-throughput exome array for identification of novel polymorphisms associated with clinical outcome in mCRC patients treated with first-line FOLFOXIRI/BEV versus FOLFIRI/BEV (TRIBE trial; NCT00719797).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3632-3632 | 2.2 | |
| 100 | Biomarker validation study: Genes involved in ubiquitin proteasome system (UPS) dependent EGFR-degradation for prediction of efficacy in metastatic colorectal cancer patients treated with cetuximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3571-3571 | 2.2 | |
| 99 | Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3537-3537 | 2.2 | |
| 98 | Common genetic variants in genes involved in the Hippo pathway: Novel biomarkers in metastatic colorectal cancer patients treated with irinotecan plus cetuximab.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14523-e14523 | 2.2 | |
| 97 | Genetic variants of CBP and SOX9 to predict clinical outcome in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI and bevacizumab (FOLFIRI/BEV).. <i>Journal of Clinical Oncology</i> , 2014 , 32, e14528-e14528 | 2.2 | |

| | | | |
|----|--|------|------|
| 96 | BRAF and KRAS mutations in liver-resected metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 476-476 | 2.2 | |
| 95 | The Role of Metronomic Chemotherapy in the Treatment of Metastatic Colorectal Cancer Patients 2014 , 135-142 | | |
| 94 | Liquid biopsy: monitoring cancer-genetics in the blood. <i>Nature Reviews Clinical Oncology</i> , 2013 , 10, 472-484 | 11.4 | 1134 |
| 93 | Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 188-94 | 3.8 | 21 |
| 92 | Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. <i>British Journal of Cancer</i> , 2013 , 108, 2549-56 | 8.7 | 45 |
| 91 | Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients. <i>European Journal of Cancer</i> , 2013 , 49, 1501-8 | 7.5 | 15 |
| 90 | FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). <i>Annals of Oncology</i> , 2013 , 24, 2062-7 | 10.3 | 74 |
| 89 | Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 2261-72 | 6.1 | 17 |
| 88 | Caveolin-1 is a novel regulator of K-RAS-dependent migration in colon carcinogenesis. <i>International Journal of Cancer</i> , 2013 , 133, 43-57 | 7.5 | 36 |
| 87 | Reply: Comment on 'Histopathologic evaluation of liver metastases from colorectal cancer patients treated with FOLFOXIRI plus bevacizumab'. <i>British Journal of Cancer</i> , 2013 , 109, 3129-30 | 8.7 | 2 |
| 86 | FOLFOXIRI/Bevacizumab Versus FOLFIRI/Bevacizumab as First-Line Treatment in Unresectable Metastatic Colorectal Cancer: Results of Phase III Tribe Trial by Gono Group. <i>Annals of Oncology</i> , 2013 , 24, iv21 | 10.3 | 4 |
| 85 | Conference Scene: Annual Meeting of the American Society of Clinical Oncology. <i>Colorectal Cancer</i> , 2013 , 2, 401-404 | 0.8 | |
| 84 | Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. <i>Colorectal Cancer</i> , 2013 , 2, 411-417 | 0.8 | 0 |
| 83 | Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. <i>PLoS ONE</i> , 2013 , 8, e66774 | 3.7 | 55 |
| 82 | FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3505-3505 | 2.2 | 28 |
| 81 | Gene expression profiles and tumor locations in colorectal cancer (left vs. right vs. rectum).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3527-3527 | 2.2 | 7 |
| 80 | Analysis of NRAS mutation as poor prognostic indicator and predictor of resistance to anti-EGFR monoclonal antibodies (anti-EGFRs) in metastatic colorectal cancer (mCRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3613-3613 | 2.2 | 3 |
| 79 | Metronomic capecitabine (cape) and cyclophosphamide (CTX) for refractory metastatic colorectal cancer (mCRC): Results of a phase II trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e14577-e14577 | 2.2 | 1 |

| | | | |
|----|--|------|-----|
| 78 | FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 336-336 | 2.2 | 20 |
| 77 | Circulating angiogenic factors as predictors of benefit from bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): Translational analyses from the phase III BEBYP trial.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 382-382 | 2.2 | 1 |
| 76 | Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 393-393 | 2.2 | |
| 75 | Correlation of messenger RNA expression patterns of ERCC1, TS, EGFR, and VEGFR2 with KRAS and BRAF mutational status in advanced colorectal cancer: Implications for targeted therapies.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 383-383 | 2.2 | 0 |
| 74 | Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer: meta-analytical estimation and implications for therapeutic strategies. <i>Cancer</i> , 2012 , 118, 1523-32 | 6.4 | 32 |
| 73 | PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients. <i>Journal of Cellular Physiology</i> , 2012 , 227, 927-33 | 7 | 5 |
| 72 | Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. <i>Annals of Oncology</i> , 2012 , 23, 1706-12 | 10.3 | 29 |
| 71 | Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012 , 19, 528-35 | 2.8 | 2 |
| 70 | The possible role of chemotherapy in antiangiogenic drug resistance. <i>Medical Hypotheses</i> , 2012 , 78, 646-8 | 3.8 | 15 |
| 69 | Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 71-6 | 3.8 | 15 |
| 68 | EZH2 polymorphism and benefit from bevacizumab in colorectal cancer: another piece to the puzzle. <i>Annals of Oncology</i> , 2012 , 23, 1370-1371 | 10.3 | 7 |
| 67 | An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. <i>Annals of Oncology</i> , 2012 , 23, 1207-1213 | 10.3 | 36 |
| 66 | Upfront Chemotherapy Regimens in Unresectable Disease: One, Two, or Three Cytotoxics?. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 153-160 | 1 | |
| 65 | . <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 263-271 | 1 | 1 |
| 64 | Cancer dormancy: a model of early dissemination and late cancer recurrence. <i>Clinical Cancer Research</i> , 2012 , 18, 645-53 | 12.9 | 140 |
| 63 | Circulating endothelial cells and their apoptotic fraction are mutually independent predictive biomarkers in Bevacizumab-based treatment for advanced colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012 , 138, 1187-96 | 4.9 | 24 |
| 62 | Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. <i>Angiogenesis</i> , 2012 , 15, 275-86 | 10.6 | 53 |
| 61 | "HER majesty's a pretty nice girl but she changes from day to day". <i>Journal of Clinical Oncology</i> , 2012 , 30, 465-6; author reply 466-7 | 2.2 | 1 |

| | | | |
|----|--|------|-----|
| 60 | High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease. <i>Oncologist</i> , 2012 , 17, 823-9 | 5.7 | 67 |
| 59 | Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer. <i>Annals of Oncology</i> , 2012 , 23, 135-141 | 10.3 | 60 |
| 58 | Influence of sex on the survival of patients with esophageal cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2265-72 | 2.2 | 85 |
| 57 | Prospective evaluation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI plus bevacizumab (BV).. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3518-3518 | 2.2 | 1 |
| 56 | Prospective study of EGFR intron 1 CA tandem repeats to predict factor benefit from cetuximab and irinotecan.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3540-3540 | 2.2 | 1 |
| 55 | LMTK3 polymorphism in patients with metastatic colon cancer.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 471-471 | 2.2 | 4 |
| 54 | Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011 , 11, 247 | 4.8 | 61 |
| 53 | Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. <i>British Journal of Cancer</i> , 2011 , 104, 1786-90 | 8.7 | 55 |
| 52 | Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2011 , 104, 1262-9 | 8.7 | 77 |
| 51 | Cytotoxic triplets plus a biologic: state-of-the-art in maximizing the potential of up-front medical treatment of metastatic colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 519-31 | 5.4 | 3 |
| 50 | Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status. <i>Critical Reviews in Oncology/Hematology</i> , 2011 , 78, 243-51 | 7 | 26 |
| 49 | Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 21-30 | 9.7 | 131 |
| 48 | Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients. <i>Annals of Oncology</i> , 2011 , 22, 1141-1146 | 10.3 | 46 |
| 47 | Should oncologists be aware in their clinical practice of KRAS molecular analysis?. <i>Journal of Clinical Oncology</i> , 2011 , 29, e206-7; author reply e208-9 | 2.2 | 15 |
| 46 | Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?. <i>British Journal of Cancer</i> , 2010 , 102, 1076-1077 | 8.7 | 1 |
| 45 | Host genetic variants in the IGF binding protein-3 impact on survival of patients with advanced gastric cancer treated with palliative chemotherapy. <i>Pharmacogenomics</i> , 2010 , 11, 1247-56 | 2.6 | 5 |
| 44 | High concordance of BRAF status between primary colorectal tumours and related metastatic sites: implications for clinical practice. <i>Annals of Oncology</i> , 2010 , 21, 1565 | 10.3 | 32 |
| 43 | Capecitabine after gastrectomy for advanced gastric cancer: have we got the patient right?. <i>Annals of Oncology</i> , 2010 , 21, 181 | 10.3 | 2 |

| | | | |
|----|--|------|-----|
| 42 | Palliative treatment of unresectable metastatic colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 63-77 | 4 | 16 |
| 41 | Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"? <i>Journal of Clinical Oncology</i> , 2010 , 28, e173-4; author reply e175-6 | 2.2 | 3 |
| 40 | Immunological effects of bevacizumab-based treatment in metastatic colorectal cancer. <i>Oncology</i> , 2010 , 79, 187-96 | 3.6 | 59 |
| 39 | Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 190-1 | 19.4 | 3 |
| 38 | Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. <i>Lancet Oncology</i> , 2010 , 11, 845-52 | 21.7 | 204 |
| 37 | Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan. <i>Pharmacogenomics Journal</i> , 2010 , 10, 458-64 | 3.5 | 102 |
| 36 | Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. <i>Journal of Experimental and Clinical Cancer Research</i> , 2010 , 29, 58 | 12.8 | 41 |
| 35 | Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. <i>Annals of Oncology</i> , 2010 , 21, 2382-2389 | 10.3 | 78 |
| 34 | Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients. <i>Current Cancer Drug Targets</i> , 2010 , 10, 37-45 | 2.8 | 8 |
| 33 | Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 559-66 | 3.5 | 5 |
| 32 | Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. <i>International Journal of Cancer</i> , 2010 , 127, 1941-7 | 7.5 | 56 |
| 31 | Beyond KRAS: perspectives on new potential markers of intrinsic and acquired resistance to epidermal growth factor receptor inhibitors in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009 , 1, 167-81 | 5.4 | 6 |
| 30 | Variations in the interleukin-1 receptor antagonist gene impact on survival of patients with advanced colorectal cancer. <i>Pharmacogenomics Journal</i> , 2009 , 9, 78-84 | 3.5 | 18 |
| 29 | Do we need biopsies of metastases for colorectal cancer patients?. <i>British Journal of Cancer</i> , 2009 , 101, 374-5; author reply 376 | 8.7 | 2 |
| 28 | Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy. <i>British Journal of Cancer</i> , 2009 , 100, 881-7 | 8.7 | 139 |
| 27 | A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 100, 1720-4 | 8.7 | 27 |
| 26 | Cigarettes smoking habit may reduce benefit from cetuximab-based treatment in advanced colorectal cancer patients. <i>Expert Opinion on Biological Therapy</i> , 2009 , 9, 945-9 | 5.4 | 12 |
| 25 | Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. <i>Annals of Surgery</i> , 2009 , 249, 420-5 | 7.8 | 192 |

| | | | |
|----|--|------|-----|
| 24 | Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. <i>BMC Cancer</i> , 2009 , 9, 303 | 4.8 | 60 |
| 23 | VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. <i>International Journal of Colorectal Disease</i> , 2009 , 24, 165-70 | 3 | 39 |
| 22 | A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 965-9 | 3.5 | 11 |
| 21 | Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. <i>British Journal of Clinical Pharmacology</i> , 2009 , 67, 132-4 | 3.8 | 8 |
| 20 | Refractory neuroendocrine tumor-response to liposomal doxorubicin and capecitabine. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 670-4 | 19.4 | 3 |
| 19 | KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2009 , 101, 715-21 | 8.7 | 450 |
| 18 | PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2622-9 | 2.2 | 368 |
| 17 | Long-Term Outcome of Unresectable Metastatic Colorectal Cancer: Does Adjuvant Chemotherapy Play a Role After Resection?. <i>Annals of Surgery</i> , 2009 , 250, 655 | 7.8 | |
| 16 | First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients 2009 , 285-293 | | |
| 15 | Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy. <i>British Journal of Cancer</i> , 2008 , 99, 716-21 | 8.7 | 28 |
| 14 | Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 7-14 | 3.8 | 15 |
| 13 | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. <i>Pharmacogenomics Journal</i> , 2008 , 8, 278-88 | 3.5 | 93 |
| 12 | Molecular predictive factors of response to anti-EGFR antibodies in colorectal cancer patients. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 86-90 | 1.6 | 2 |
| 11 | Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1427-34 | 2.2 | 113 |
| 10 | A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. <i>British Journal of Cancer</i> , 2008 , 98, 1312-9 | 8.7 | 57 |
| 9 | High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. <i>Oncologist</i> , 2008 , 13, 1270-5 | 5.7 | 197 |
| 8 | EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach. <i>Pharmacogenomics</i> , 2008 , 9, 55-69 | 2.6 | 11 |
| 7 | First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?. <i>Current Opinion in Oncology</i> , 2008 , 20, 459-65 | 4.2 | 9 |

| | | | |
|---|---|------|-----|
| 6 | Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3930-5 | 2.2 | 103 |
| 5 | Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1816-8 ² | 2.2 | 50 |
| 4 | Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1247-54 | 2.2 | 235 |
| 3 | First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2006 , 17, 1249-54 | 10.3 | 21 |
| 2 | Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4668-9; author reply 4669 | 2.2 | |
| 1 | Treatment with 5-fluorouracil/folinic acid, oxaliplatin, and irinotecan enables surgical resection of metastases in patients with initially unresectable metastatic colorectal cancer. <i>Annals of Surgical Oncology</i> , 2006 , 13, 58-65 | 3.1 | 140 |